ArticleCancer chemotherapy and pharmacology2021

A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.

Katharine A Collier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.